A Single Ketamine Infusion Combined With Music for Suicidal Ideation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04658420|
Recruitment Status : Not yet recruiting
First Posted : December 8, 2020
Last Update Posted : May 7, 2021
|First Submitted Date ICMJE||November 16, 2020|
|First Posted Date ICMJE||December 8, 2020|
|Last Update Posted Date||May 7, 2021|
|Estimated Study Start Date ICMJE||July 1, 2021|
|Estimated Primary Completion Date||December 2022 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Scale for Suicide Ideation (SSI) [ Time Frame: 4 weeks ]
Clinician administered scale. Score range 0-38. Higher scores are indicative of increased suicidal ideation. The primary efficacy evaluation for each panel will be the change in SSI total score from baseline, prior to the first IV ketamine dose, to 4 weeks after IV ketamine treatment. 25 % reduction in score will be deemed treatment response, 50% reduction will be determined to be treatment remission.
|Original Primary Outcome Measures ICMJE||Same as current|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Pre-specified Outcome Measures||Not Provided|
|Original Other Pre-specified Outcome Measures||Not Provided|
|Brief Title ICMJE||A Single Ketamine Infusion Combined With Music for Suicidal Ideation|
|Official Title ICMJE||A Single Ketamine Infusion Combined With Music for Suicidal Ideation During a Depressive Episode: A Randomized Open Label Clinical Trial|
|Brief Summary||Suicidal ideation (SI) associated with major and bipolar depression is commonly seen in a wide range of clinical practice situations including the emergency room (ER). Current treatment regimens are often unsatisfactory. About a third of patients fail to respond to currently available therapy, and there are no currently FDA indicated rapid acting treatments for SI. Suboptimal outcomes have triggered the search for new, well-tolerated and more effective forms of treatment. Small clinical trials suggest that low dose (0.5mg/kg) ketamine is safe and effective for SI. We believe adding music during ketamine infusion may reduce anxiety and lead to more reduced SI based on available evidence. We are testing the hypothesis that a single infusion of ketamine combined with music enhances tolerability and improves outcomes in the treatment of SI when combined with treatment as usual in a factorial study design. One treatment with Ketamine + music will be compared to compared to one-time treatment with ketamine alone, music alone, or treatment as usual. 50 individuals with a depressive episode and suicidal ideation will receive intravenous (IV) ketamine 0.5mg/kg infused over 40 minutes once with 60 minutes of music, 50 individuals will receive IV ketamine without music, 50 subjects will receive 60 minutes of music once, and 50 patients will receive treatment as usual without ketamine or music. We anticipate that the ketamine + music group will have statistically significant indices of improvement in the primary outcome, suicidal ideation scores on the Scale for Suicidal Ideation (SSI) 4 weeks after the ketamine infusion. Secondary outcomes will include depression scores on the MontgomeryÅsberg Depression Rating Scale (MADRS) scale, adverse effects, and SSI scores at the end of 4 weeks. If, as we anticipate, the results indicate success of ketamine + music for SI, the work will identify new opportunities to more effectively manage patients with depression and suicidal ideation presenting to the ER.|
Ketamine is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist traditionally used as a general anesthetic. Recent double blinded randomized control trials of intravenous (IV) ketamine infusions have been well-tolerated and demonstrated a rapid onset of antidepressant effect, most notably in subjects with treatment-resistant depression (TRD) and treatment-resistant bipolar depression.
Significance. The outcomes of current therapy for depression are poor, with roughly a third of patient's failing to improve or regressing. The patients are high risk for suicide and the need for rapid acting, durable treatments for reduction of suicidal ideation is paramount.
Ketamine has been shown to improve suicidal ideation for at least 6 weeks in the largest study of ketamine for SI to date in subjects recruited to participate in the clinical trial and admitted to a research facility. We intend to test ketamine in a more pragmatic trial in the ER in patients who are not actively recruited, but report SI to ER staff or have SI as a chief complaint.
Overview. In the current open label randomized control trial, we will examine the suicidal ideation reducing efficacy of IV ketamine combined with music and treatment as usual in four groups. All four groups will receive treatment as usual as defined above (potential hospitalization, medication, psychotherapy, outpatient referrals, suicide safety planning). A factorial design is being implemented to test two interventions independently and combined: ketamine and music. One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music will be compared to 3 other groups: One group will receive the same dose of ketamine without music, one group will one hour of music without ketamine, and one group will receive neither music nor ketamine. During the 4-week follow up interval, subjects from both groups will be contacted by phone for weekly assessment of depression, SI and quality of life.
A playlist by composer Nils Frahm will be played for 60 minutes. The music is instrumental, relaxing and subjectively thought to be uplifting by patients who have listened to the music during ketamine infusions performed previously by the PI for treatment of resistant depression. Music can be previewed at the link below:
Patients will be screened for study entry by the emergency room (ER) treating physician who will be available 24 hours a day who will notify the clinical trials research staff that a subject is available to be screened. Dr. Robert Creath Er attending will be the primary coordinator of Er services. The clinical trials staff that will be assigned to the project by the UTHET north campus department of clinical research. will then screen the subject for entry to the study, and perform the informed consent process. The subject will then be randomized by clinical trials staff using block randomization to each group. A 1:1 assignment to each group will be implemented with permuted blocks between 4 and 6 with equal probability. Patients entering the study will be voluntarily admitted to the hospital or monitored in the ER for a minimum of 2 hours after the first IV ketamine or music treatment and discharged when deemed to not be a suicide risk by a treating physician. A driver will be required to take the subject home if discharged the same day as the ketamine treatment. Subjects deemed to be a continued risk to themselves or others will be admitted as per clinician discretion which is considered treatment as usual. The ER nurse will be administering the sub-anesthetic dose of ketamine. Vital signs including, blood pressure, pulse oxygenation will be monitored at fifteen-minute intervals during the infusion, and will be recorded for 30 minutes after the infusion at fifteen minute intervals. Subjects will be followed up by phone at weekly intervals and voluntary hospitalization will be recommended for patients with SSI score of ≥4. Psychotropic medications will be adjusted and optimized at the discretion of the treating physicians at study entry. Medications may be modified during the 4-week study interval in line with standard practice. Informed consent will be obtained for all participants. Informed consent will be obtained in person when possible or by the Teams telemedicine app when necessary if research staff is unavailable on site.
The primary outcome measure of this study will be treatment response, defined as a ≥50% score reduction in the SSI from baseline to 4 weeks after the first ketamine injection. Remission will be defined as a ≥50% reduction in SSI score with score ≤4. The SSI will be administered at baseline, prior to each treatment and 24 hours after IV ketamine administration, then every week during the symptom monitoring follow-up period of 4 weeks. The clinician-rated SSI assesses current severity of suicidal ideation with 19 items scaled from 0 (least severe) to 2 (most severe). Medications may be adjusted during the study interval. Secondary outcome will be change in MADRS and SSI score from baseline to 4 weeks after the treatment. Raters will be blinded to the subject treatment group.
During the 4-week follow up participants will be contacted by phone with follow-up questions regarding their overall health status, mood and clinical state using MADRS, SSI, QIDS and other clinical scales listed below.
Study/Design. Patients with clinically documented depression with SI will be screened for diagnosis of depressive episode with the Mini-International Neuropsychiatric Interview (MINI), a structured interview of psychiatric disorders, at baseline to establish the presence of a major depressive episode. The depressive episode could be associated with major depressive disorder, bipolar disorder or substance induced depressive disorder.
Portable speakers will be provided playing relaxing music prior to and during the administration of ketamine for groups 2 and 3 (Nils Frahm playlist-modern classical composer). This music has been previously used at Christus Mother Francis for therapeutic ketamine use with good results. Subjects will be inform that music can be stopped by request at any time. Informed consent and screening will be performed in the UTHET north campus clinical trials staff at initial presentation. Follow up assessments during weeks 1-4 will be done by phone. Clinical research staff will randomize subjects to treatment groups as documented above. Ketamine IV will be supplied by the UT Health East Texas pharmacy. The administration of ketamine will be initiated by the emergency room nurse with ACLS certified physician supervision.
Prior to the treatment, patients will be undergo psychiatric interview by the University of Texas Health center at Tyler psychiatric ER consult liaison team as per standard practice. An ACLS certified physician will be nearby in the ER post-procedure for 1 hour or until a clinician deems patient is clinically stable.
We plan on utilizing the monitoring protocol advised by the American Psychiatric Association consensus statement:
"(1) assessment of respiratory status (i.e., oxygen saturation or end-tidal CO2); (2) assessment of cardiovascular function (blood pressure and heart rate, reported on a regular basis every 15 minutes); (3) assessment of the level of consciousness or other documented assessment of responsiveness; and (4) delineation of criteria for stopping the infusion and a clear plan for managing cardiovascular or behavioral events during treatment."
Adverse events will be monitored and recorded throughout the study. The most common side effects associated with ketamine are nausea, vomiting, dizziness, double vision, drowsiness, elevated blood pressure, tachycardia, anxiety, dissociation (feeling strange and disconnected from the world), and confusion. Delirium, hallucinations, and nightmares have been associated with high dose ketamine, but are not common side effects in subanesthetic ketamine treatment. The subanesthetic dose of 0.5 mg/kg has been documented to be safe and well tolerated in numerous clinical trials in the treatment of suicidal thoughts.
Rare but serious possible adverse event associated with ketamine include:
Cardiac arrest, diabetes insipidus, anaphylaxis, ocular hypertension, increased intracranial pressure, arrythmia exacerbation or apnea.
Digital pulse oximetry, blood pressure, heart rate, and respiratory rate will be monitored throughout the injection at 15 minute intervals with a recovery period similar to recent study of IV ketamine for PTSD and TRD performed at the Minneapolis VA. Vital signs, the Clinician Administered Dissociative States Scale (CADSS) will be assessed pre-dose, at 40 minutes after ketamine infusion has started. Hypertensive emergency, respiratory failure or cardiac arrest is not known to have occurred in previous clinical trials of IV ketamine for treatment of depression. Emergency room physicians will be notified and render care in the event of unexpected medical emergencies. The infusions will be stopped if a patient requests stopping the infusion, becomes agitated, or goes into respiratory failure or cardiac arrest. Medical emergencies will be managed by ACLS certified ER physicians. Code BERT will be called as necessary if a patient becomes acutely agitated and presents a danger to themselves or others.
Medications will be optimized as per standard practice throughout the 4-week study. Suicide safety plans, referrals to outpatient treatments will done as per standard practice. Participants will be directed to contact the nearest ER in case of emergency after initial hospital discharge. Participants will be contacted weekly during the 4-week study period to review the patient's health status and administer clinical scales by phone.
Clinical assessment. Informed consent will be obtained. This evaluation will obtain family history and demographic data. We will perform a urine drug screening (UDS) to rule out recent undisclosed use of illicit substances that may exclude subjects from the study. Demographic information is obtained through a standardized form and covers age, race, gender, education (information both on siblings and their parents), religion, and socioeconomic status.
Participants will fill out the mood questionnaires rating the severity of the clinical symptoms. Participants will be asked about previous medications they have taken for mental health disorders and general medical conditions. Results will be stored in a secure location by the department of clinical research. Selected mood assessment questionnaires will be administered by our clinical research staff including the MINI Interview. This is the standard psychiatric research evaluation for ascertainment of psychiatric diagnosis in the context of research studies. It is a comprehensive structured interview for determining axis I diagnosis according to the DSM-V to be administered at study entry and takes approximately 15 minutes. We will also use the Montgomery Åsberg Depression Rating Scale (MADRS): this scale rates depressive symptoms, and its psychometric properties are well-established. We will assess SI with the Suicidal Scale Instrument. The clinician-rated SSI assessed current severity of suicidal ideation with 19 items scaled from 0 (least severe) to 2 (most severe). We will also assess dissociation with the Clinician-Administered Dissociative States Scale (CADSS): Frequency of administration: After every treatment, to monitor the dissociative side effects status post infusion.
Self-report questionnaires to assess mood, and quality of life will include Quick inventory of depressive symptomatology QIDS-SR to measure self-reported depressive symptoms, weekly and the World health organization quality of life scale.
|Study Type ICMJE||Interventional|
|Study Phase ICMJE||Phase 2|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Factorial Assignment
Intervention Model Description:
All four groups will receive treatment as usual as defined above (potential approved hospitalization, medication, psychotherapy, outpatient referrals, suicide safety planning). A factorial design is being implemented to test four interventions. One group will receive IV ketamine 0.5mg/kg infused over forty minutes with one hour of pre-planned music will be compared to 3 other groups: One group will receive the same dose of ketamine without music, one group will one hour of music without ketamine, and one group will receive neither music nor ketamine. During the 4-week follow up interval, subjects from both groups will be contacted by phone for weekly assessment of depression, SI and quality of life.Masking: None (Open Label)
Primary Purpose: Treatment
|Study Arms ICMJE||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Not yet recruiting|
|Estimated Enrollment ICMJE
|Original Estimated Enrollment ICMJE||Same as current|
|Estimated Study Completion Date ICMJE||April 2023|
|Estimated Primary Completion Date||December 2022 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
Uncontrolled clinically significant medical conditions such as:
|Ages ICMJE||18 Years to 64 Years (Adult)|
|Accepts Healthy Volunteers ICMJE||No|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT04658420|
|Other Study ID Numbers ICMJE||2020-042
KL2TR003168 ( U.S. NIH Grant/Contract )
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||
|IPD Sharing Statement ICMJE||
|Current Responsible Party||The University of Texas Health Science Center at Tyler|
|Original Responsible Party||Same as current|
|Current Study Sponsor ICMJE||The University of Texas Health Science Center at Tyler|
|Original Study Sponsor ICMJE||Same as current|
|PRS Account||The University of Texas Health Science Center at Tyler|
|Verification Date||May 2021|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP